Keytruda® (pembrolizumab), Lenvima® (lenvatinib) – Expanded indication
August 10, 2021 - The FDA approved Merck’s Keytruda (pembrolizumab), in combination with Eisai’s Lenvima (lenvatinib), for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
Download PDF
